FDA Clears Quantum BioPharma's Lucid-MS for Phase 2 Trial in Multiple Sclerosis
QNTM sits 76% above its 52-week low of $2.07 on elevated volume (5.6× avg).
Summary
The FDA has cleared Quantum BioPharma's IND application for Lucid-MS, allowing the company to advance its lead multiple sclerosis candidate into Phase 2 clinical development. This is a critical regulatory milestone that moves the drug from early safety testing into a randomized, double-blind, placebo-controlled efficacy study. The clearance follows a prior clinical hold in June 2026, making this a significant turnaround. With a market cap of just $23 million, positive Phase 2 data could dramatically revalue the company. Trial start-up activities are underway, though enrollment timelines remain uncertain. The company reported over $10 million in cash and liquid assets as of March 31, 2026, providing some runway for the trial.
At the time of this announcement, QNTM was trading at $3.64 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $23.3M. The 52-week trading range was $2.07 to $31.91. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: FinanceWire.